These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

560 related items for PubMed ID: 25419615

  • 1. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.
    Arvin AM, Wolinsky JS, Kappos L, Morris MI, Reder AT, Tornatore C, Gershon A, Gershon M, Levin MJ, Bezuidenhoudt M, Putzki N.
    JAMA Neurol; 2015 Jan; 72(1):31-9. PubMed ID: 25419615
    [Abstract] [Full Text] [Related]

  • 2. Fingolimod and risk of varicella-zoster virus infection: back to the future with an old infection and a new drug.
    Tyler KL.
    JAMA Neurol; 2015 Jan; 72(1):10-3. PubMed ID: 25420159
    [No Abstract] [Full Text] [Related]

  • 3. T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
    Ricklin ME, Lorscheider J, Waschbisch A, Paroz C, Mehta SK, Pierson DL, Kuhle J, Fischer-Barnicol B, Sprenger T, Lindberg RL, Kappos L, Derfuss T.
    Neurology; 2013 Jul 09; 81(2):174-81. PubMed ID: 23700335
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD.
    Lancet Neurol; 2014 Jun 09; 13(6):545-56. PubMed ID: 24685276
    [Abstract] [Full Text] [Related]

  • 5. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):402-15. PubMed ID: 20089954
    [Abstract] [Full Text] [Related]

  • 6. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA, TRANSFORMS Study Group.
    Lancet Neurol; 2011 Jun 04; 10(6):520-9. PubMed ID: 21571593
    [Abstract] [Full Text] [Related]

  • 7. Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
    Harrer A, Wipfler P, Pilz G, Oppermann K, Haschke-Becher E, Afazel S, Kraus J, Trinka E, Sellner J.
    Int J Mol Sci; 2015 Sep 10; 16(9):21832-45. PubMed ID: 26378517
    [Abstract] [Full Text] [Related]

  • 8. The frequency of varicella-zoster virus infection in patients with multiple sclerosis receiving fingolimod.
    Aramideh Khouy R, Karampoor S, Keyvani H, Bokharaei-Salim F, Monavari SH, Taghinezhad S, Etemadifar M, Esghaei M.
    J Neuroimmunol; 2019 Mar 15; 328():94-97. PubMed ID: 30610966
    [Abstract] [Full Text] [Related]

  • 9. Antigen-shift in varicella-zoster virus-specific T-cell immunity over the course of Fingolimod-treatment in relapse-remitting multiple sclerosis patients.
    Matko S, Akgün K, Tonn T, Ziemssen T, Odendahl M.
    Mult Scler Relat Disord; 2020 Feb 15; 38():101859. PubMed ID: 31855843
    [Abstract] [Full Text] [Related]

  • 10. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):387-401. PubMed ID: 20089952
    [Abstract] [Full Text] [Related]

  • 11. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis.
    Zarbin MA, Jampol LM, Jager RD, Reder AT, Francis G, Collins W, Tang D, Zhang X.
    Ophthalmology; 2013 Jul 04; 120(7):1432-9. PubMed ID: 23531349
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.
    Agashivala N, Kim E.
    Clin Ther; 2012 Jul 04; 34(7):1583-90. PubMed ID: 22749258
    [Abstract] [Full Text] [Related]

  • 13. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N, Lahoz R, Reynolds T, Korn JR.
    Curr Med Res Opin; 2014 Aug 04; 30(8):1461-71. PubMed ID: 24754349
    [Abstract] [Full Text] [Related]

  • 14. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.
    Cohen M, Maillart E, Tourbah A, De Sèze J, Vukusic S, Brassat D, Anne O, Wiertlewski S, Camu W, Courtois S, Ruet A, Debouverie M, Le Page E, Casez O, Heinzlef O, Stankoff B, Bourre B, Castelnovo G, Rico A, Berger E, Camdessanche JP, Defer G, Clavelou P, Al Khedr A, Zephir H, Fromont A, Papeix C, Brochet B, Pelletier J, Lebrun C, Club Francophone de la Sclérose en Plaques Investigators.
    JAMA Neurol; 2014 Apr 04; 71(4):436-41. PubMed ID: 24566807
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
    Lee S, Baxter DC, Limone B, Roberts MS, Coleman CI.
    J Med Econ; 2012 Apr 04; 15(6):1088-96. PubMed ID: 22583065
    [Abstract] [Full Text] [Related]

  • 16. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
    Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L, FREEDOMS study group.
    Lancet Neurol; 2012 May 04; 11(5):420-8. PubMed ID: 22494956
    [Abstract] [Full Text] [Related]

  • 17. Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients.
    König C, Kleber M, Reinhardt H, Knop S, Wäsch R, Engelhardt M.
    Ann Hematol; 2014 Mar 04; 93(3):479-84. PubMed ID: 24318541
    [Abstract] [Full Text] [Related]

  • 18. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
    He A, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Girard M, Pucci E, Iuliano G, Alroughani R, Oreja-Guevara C, Fernandez-Bolaños R, Grand'Maison F, Sola P, Spitaleri D, Granella F, Terzi M, Lechner-Scott J, Van Pesch V, Hupperts R, Sánchez-Menoyo JL, Hodgkinson S, Rozsa C, Verheul F, Butzkueven H, Kalincik T, MSBase Study Group.
    JAMA Neurol; 2015 Apr 04; 72(4):405-13. PubMed ID: 25665031
    [Abstract] [Full Text] [Related]

  • 19. Oral fingolimod (FTY720) for relapsing multiple sclerosis.
    Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW, FTY720 D2201 Study Group.
    N Engl J Med; 2006 Sep 14; 355(11):1124-40. PubMed ID: 16971719
    [Abstract] [Full Text] [Related]

  • 20. Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis.
    Kohlmann R, Salmen A, Chan A, Knabbe C, Diekmann J, Brockmeyer N, Skaletz-Rorowski A, Michalik C, Gold R, Überla K.
    Mult Scler; 2015 Dec 14; 21(14):1823-32. PubMed ID: 25828755
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.